US-listed stock · Healthcare · Pharmaceuticals and vaccines · close 16 Nov 2026
Close
$28.86
Day change
-0.1%
1 month
-2.4%
6 months
+13.9%
1 year
+15.2%
3 years
-3.1%
5 years
-41.8%
From 52-week high
-6.3%
Weinstein stage
Stage 2
Pfizer closed at $28.86 on 16 Nov 2026. Over the past year it has gained 15.2%, and over five years -42% in all (-10.3% a year). It is 6.3% below its 52-week closing high of $30.79, set on 4 Nov 2026, and 21.9% above its 52-week closing low of $23.67. The price is above its 200-day average of $27.00 - an average that is itself still rising. On Stan Weinstein's stage analysis it is in Stage 2: advancing - above a rising 150-day average. Its deepest fall from a peak in the period shown was 65%.
Price, RSI and MACD
Price · +12.5% over the period
RSI (14) · 44.7
MACD (12, 26, 9) · histogram -0.21
Price · +15.2% over the period
RSI (14) · 44.7
MACD (12, 26, 9) · histogram -0.21
Price · +10.2% over the period
RSI (14) · 44.7
MACD (12, 26, 9) · histogram -0.21
Price · -2.1% over the period
RSI (14) · 44.7
MACD (12, 26, 9) · histogram -0.21
Price · -41.9% over the period
RSI (14) · 44.7
MACD (12, 26, 9) · histogram -0.21
Price: daily close adjusted for stock splits, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.
50-day average $28.81 · 200-day average $27.00 · 52-week closing range $23.67 – $30.79
Daily closes to 16 Nov 2026, adjusted for stock splits (not dividends), from Google Finance and Yahoo Finance. US stock prices in US dollars; index levels in points. Figures may be delayed and are for information only.
For research & education only — not investment advice or a recommendation to buy or sell any security. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by any exchange or index provider. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.